5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion - PubMed (original) (raw)

Editorial

5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion

Brian G Feagan. Clin Gastroenterol Hepatol. 2004 May.

No abstract available

PubMed Disclaimer

Comment on

• Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
  Hanauer SB, Strömberg U. Hanauer SB, et al. Clin Gastroenterol Hepatol. 2004 May;2(5):379-88. doi: 10.1016/s1542-3565(04)00122-3. Clin Gastroenterol Hepatol. 2004. PMID: 15118975

Similar articles

• Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
  Feagan BG. Feagan BG. Eur J Surg. 1998 Dec;164(12):903-9. doi: 10.1080/110241598750005066. Eur J Surg. 1998. PMID: 10029385 Review. No abstract available.
• Aminosalicylates for induction of remission or response in Crohn's disease.
  Lim WC, Hanauer S. Lim WC, et al. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008870. doi: 10.1002/14651858.CD008870. Cochrane Database Syst Rev. 2010. PMID: 21154400 Updated. Review.
• Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease.
  Rutgeerts P. Rutgeerts P. Gut. 2001 Apr;48(4):452-3. doi: 10.1136/gut.48.4.452. Gut. 2001. PMID: 11247886 Free PMC article. No abstract available.
• Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
  Kamm MA. Kamm MA. Inflamm Bowel Dis. 2005 Jun;11(6):616-7. doi: 10.1097/01.mib.0000160744.32396.02. Inflamm Bowel Dis. 2005. PMID: 15905712
• The case for using 5-aminosalicyclates in Crohn's disease: pro.
  Hanauer SB. Hanauer SB. Inflamm Bowel Dis. 2005 Jun;11(6):609-12. doi: 10.1097/01.mib.0000160743.24772.69. Inflamm Bowel Dis. 2005. PMID: 15905710

Cited by

• Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.
  Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Łodyga M, et al. Prz Gastroenterol. 2021;16(4):257-296. doi: 10.5114/pg.2021.110914. Epub 2021 Nov 19. Prz Gastroenterol. 2021. PMID: 34976235 Free PMC article.
• Cannabis for the treatment of Crohn's disease.
  Kafil TS, Nguyen TM, MacDonald JK, Chande N. Kafil TS, et al. Cochrane Database Syst Rev. 2018 Nov 8;11(11):CD012853. doi: 10.1002/14651858.CD012853.pub2. Cochrane Database Syst Rev. 2018. PMID: 30407616 Free PMC article.
• Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.
  Ma C, Ascoytia C, McCarrier KP, Martin M, Feagan BG, Jairath V. Ma C, et al. Dig Dis Sci. 2018 Oct;63(10):2555-2563. doi: 10.1007/s10620-018-5181-6. Epub 2018 Jun 29. Dig Dis Sci. 2018. PMID: 29959726
• Aminosalicylates for induction of remission or response in Crohn's disease.
  Lim WC, Wang Y, MacDonald JK, Hanauer S. Lim WC, et al. Cochrane Database Syst Rev. 2016 Jul 3;7(7):CD008870. doi: 10.1002/14651858.CD008870.pub2. Cochrane Database Syst Rev. 2016. PMID: 27372735 Free PMC article. Review.
• Herb-partitioned moxibustion upregulated the expression of colonic epithelial tight junction-related proteins in Crohn's disease model rats.
  Ji R, Wang A, Shang H, Chen L, Bao C, Wu L, Wu H, Shi Y. Ji R, et al. Chin Med. 2016 Apr 26;11:20. doi: 10.1186/s13020-016-0090-0. eCollection 2016. Chin Med. 2016. PMID: 27118991 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information